ClearPoint Neuro (CLPT) CEO Joseph Burnett Exercises Options

What Happened
Joseph M. Burnett, President, CEO and a director of ClearPoint Neuro (CLPT), exercised stock options on 2026-09-02 to acquire 12,517 common shares at an exercise price of $3.47 per share, for a cash outlay of $43,434. The filing also shows the corresponding derivative (the option) converted/disposed at $0, which reflects conversion of the option into shares rather than a sale.

Key Details

• Transaction date: 2026-09-02; Form filed: 2026-09-03 (timely filing).
• Action code: M = Exercise/conversion of derivative.
• Shares acquired: 12,517 at $3.47 each; total paid $43,434.
• Disposition line: 12,517 @ $0 — indicates the option was converted into shares (not sold).
• Ownership after transaction: filing does not state total CLPT shares owned post-transaction.
• Footnotes: Mr. Burnett paid the exercise price in cash and retained all shares. The shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Mr. Burnett as trustee. The option’s original grant date was Aug 15, 2019, with a 3-year vesting schedule (20% at 1 year, 40% at 2 years, 40% at 3 years).

Context
This was an option exercise (not a cashless sale). Because Mr. Burnett retained the shares and they are held in his trust, the transaction is a personal acquisition of stock rather than a sale or hedging action. Purchases/exercises can be interpreted by investors as a neutral-to-bullish signal, but the filing contains no stated motivation and does not itself predict future performance.